Physician

Swetha Makkapati

According to 2025 Medicare claims, Swetha Makkapati (NPI: 1629335880) practices nephrology in the Winchester, VA-WV market, with the plurality of this provider's patient population coming from Winchester City, VA. This provider's primary affiliated billing organization is RENAL PHYSICIAN ASSOCIATES OF WINCHESTER PLC (NPI: 1528142577; TIN: 208391941) and primary practice location at 22601-3344. Makkapati is affiliated with the ACO West Virginia (ACO ID: A3563) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Makkapati's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 898 traditional Medicare patients, billed 2,981 HCPCS/CPT codes, and received $241,152 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,242 prescription claims across 338 beneficiaries totaling $150,601 in drug costs, led by Xphozah (Tenapanor Hcl). Open Payments data shows 22 records totaling $526. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $46,510 to $241,152. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $52,362 and ending at $150,601. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	173	625	$46,510
2018	478	2,225	$149,633
2019	646	2,538	$187,121
2020	656	2,300	$211,093
2021	707	2,387	$244,096
2022	725	2,589	$226,297
2023	926	2,721	$256,304
2024	898	2,981	$241,152

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	69	291	$52,362
2016	73	541	$158,642
2017	63	187	$48,237
2018	140	679	$195,933
2019	153	810	$186,758
2020	198	916	$86,547
2021	244	1,116	$81,752
2022	339	1,330	$107,020
2023	355	1,383	$135,251
2024	338	1,242	$150,601

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	65	65	$161
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	150	165	$132
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	234	730	$62
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	501	828	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	329	465	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xphozah	Tenapanor Hcl	14	420	$40,835
Farxiga	Dapagliflozin Propanediol	14	1,080	$18,127
Jardiance	Empagliflozin	11	930	$14,205
Sevelamer Carbonate	Sevelamer Carbonate	46	2,599	$6,402
Cinacalcet Hcl	Cinacalcet Hcl	14	724	$3,148

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	22	$526	Ardelyx, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Swetha Makkapati?

Tedicare shows public-source Medicare data for Swetha Makkapati (NPI 1629335880), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Swetha Makkapati have ACO affiliation data?

Swetha Makkapati is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Swetha Makkapati?

Swetha Makkapati is linked to RENAL PHYSICIAN ASSOCIATES OF WINCHESTER PLC (billing NPI 1528142577) in the available physician profile data.

Does Swetha Makkapati have Open Payments data?

Swetha Makkapati has 22 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.